Patents by Inventor Marc Schiller

Marc Schiller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aqueous pharmaceutical formulation of tapentadol for oral administration
    Patent number: 11547678
    Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: January 10, 2023
    Assignee: Gruenenthal GmbH
    Inventors: Ulrich Reinhold, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts, Ulrich Feil
  • Stable formulation for parenteral administration of tapentadol
    Patent number: 11013701
    Abstract: The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 25, 2021
    Assignee: Grünenthal GmbH
    Inventors: Marc Schiller, Carlos van Hemelrijck, Stefanie Straub, Eva Wulsten, Ulrike Bertram, Ulrich Reinhold
  • Pharmaceutical dosage forms comprising 6?-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine
    Patent number: 10912763
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: February 9, 2021
    Assignee: Grünenthal GmbH
    Inventors: Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
  • PARENTERAL ADMINISTRATION OF TAPENTADOL
    Publication number: 20200215003
    Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 9, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: Thomas CHRISTOPH, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Petra BLOMS-FUNKE, Klaus SCHIENE, Ulrich FEIL
  • AQUEOUS PHARMACEUTICAL FORMULATION OF TAPENTADOL FOR ORAL ADMINISTRATION
    Publication number: 20200054584
    Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 20, 2020
    Applicant: GRÜNENTHAN GMBH
    Inventors: Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich FEIL
  • MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL
    Publication number: 20180369151
    Abstract: The invention relates to an oral pharmaceutical dosage form comprising a plurality of coated particles, wherein said coated particles comprise a core which comprises a Tapentadol component and which is coated with a controlled release coating material, wherein the controlled release coating material comprises a lubricant component and a polymer component, wherein the polymer component comprises one or more cellulose ethers and/or one or more acrylates, and wherein the pharmaceutical dosage form provides controlled release of the Tapentadol component.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 27, 2018
    Applicant: GRÜNENTHAL GMBH
    Inventors: Marc SCHILLER, Ulrich REINHOLD, Ulrike BERTRAM, Wolfgang PRANGE, Anika-Anina PHILIPP, Stefanie STRAUB, Annette GRAVE, Norbert POELLINGER
  • Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol
    Publication number: 20180133174
    Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 17, 2018
    Inventors: Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich FEIL
  • Stable Formulation for Parenteral Administration of Tapentadol
    Publication number: 20180125800
    Abstract: The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 10, 2018
    Inventors: Marc SCHILLER, Carlos van Hemelrijck, Stefanie STRAUB, Eva WULSTEN, Ulrike BERTRAM, Ulrich REINHOLD
  • Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine
    Publication number: 20160361294
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Application
    Filed: August 24, 2016
    Publication date: December 15, 2016
    Inventors: Nadja GRUENING, Marc SCHILLER, Ashish HEMANI, Chris KIRBY, Ingo FRIEDRICH, John BOTHMER, Andreas SCHOLZ
  • Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol
    Publication number: 20160346229
    Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2016
    Publication date: December 1, 2016
    Inventors: Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich FEIL
  • Stable Formulation for Parenteral Administration of Tapentadol
    Publication number: 20160279078
    Abstract: The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising Tapentadol or a physiologically acceptable salt thereof, wherein the concentration of Tapentadol is within the range of from 0.10 to 8.00 mg/mL, based on the weight of Tapentadol free base and based on the total volume of the composition; and wherein the pH value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. The invention also relates to a kit comprising the contained according to the invention in a packaging. The pharmaceutical composition according to the invention is particularly useful for treating pain, especially acute pain, preferably in pediatric patients.
    Type: Application
    Filed: March 23, 2016
    Publication date: September 29, 2016
    Inventors: Marc SCHILLER, Carlos van Hemelrijck, Stefanie STRAUB, Eva WULSTEN, Ulrike BERTRAM, Ulrich REINHOLD
  • Semisolid aqueous pharmaceutical composition containing tapentadol
    Patent number: 9446008
    Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: September 20, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Ulrich Reinhold, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts, Ulrich Feil
  • Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration
    Publication number: 20160220516
    Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Inventors: Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich FEIL
  • Parenteral Administration of Tapentadol
    Publication number: 20160106688
    Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Thomas CHRISTOPH, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Petra BLOMS-FUNKE, Klaus SCHIENE, Ulrich FEIL
  • Pharmaceutical dosage forms comprising 6?-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine
    Patent number: 9289416
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: March 22, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
  • Pharmaceutical Dosage Forms Comprising 6'-Fluoro-(N-Methyl- or N,N-Dimethyl-)-4-Phenyl-4',9'-Dihydro-3'H-Spiro[Cyclohexane-1,1'-Pyrano[3,4,b]Indol]-4-Amine
    Publication number: 20150111939
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Nadja GRUENING, Marc SCHILLER, Ashish HEMANI, Chris KIRBY, Ingo FRIEDRICH
  • Dosage form containing (S)-pantoprazole as active ingredient
    Patent number: 8758817
    Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: June 24, 2014
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Isabel Anstett-Klein, Marc Schiller, Hartmut Ney, Manfred Hartmann, Sabine Schäfer-Preuss
  • Dosage form containing pantoprazole as active ingredient
    Patent number: 8703192
    Abstract: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: April 22, 2014
    Assignee: Takeda GmbH
    Inventors: Isabel Anstett-Klein, Rango Dietrich, Hartmut Ney, Marc Schiller, Sabine Schaefer-Preuss, Manfred Hartmann
  • Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration
    Publication number: 20130022670
    Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
    Type: Application
    Filed: March 2, 2012
    Publication date: January 24, 2013
    Applicant: Gruenenthal GmbH
    Inventors: Ulrich REINHOLD, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts
  • Semisolid Aqueous Pharmaceutical Composition Containing Tapentadol
    Publication number: 20120225950
    Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 6, 2012
    Applicant: Gruenenthal GmbH
    Inventors: Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS